SynthesisFrontiers in pharmacology2026
Tumor-on-chip and cancer microphysiological platforms: knowledge structure, thematic evolution, and the emergence of organoid-integrated models, 2010-2025.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer microphysiological systems (MPS), including tumor-on-chip platforms, combine engineered microenvironments, controlled fluid transport, and tumor-relevant biological models for cancer modeling, drug testing, and translational research. Organoid-integrated chips represent one developing component within this broader field, but the publication growth, knowledge structure, and changing research priorities of cancer MPS and tumor-on-chip research have not been systematically mapped across major bibliographic databases. Methods: We performed a dual-database bibliometric analysis of publications indexed in the Web of Science Core Collection and Scopus from 2010 to 2025. Bibliometric indicators were analyzed using Bibliometrix, VOSviewer, and CiteSpace. We examined publication growth, source distribution, author and country collaboration, highly cited and co-cited references, and temporal keyword evolution. In addition, a phase-split keyword analysis was conducted to compare the research emphasis during 2010-2020 and 2021-2025. Results: A total of 476 publications were included in the final cancer MPS/tumor-on-chip corpus. Research output increased markedly after 2020 and reached 101 articles in 2025. Source, co-citation, and keyword analyses suggested a progressive shift from early emphasis on microfluidic device construction and physical culture control toward greater attention to biofabrication, tumor microenvironment reconstruction, immune-related interactions, and drug-screening and other application-oriented themes. Phase-split keyword analysis showed that recent publications placed greater attention on biological applications and translational questions while retaining a clear connection with earlier engineering-oriented research. The United States and China emerged as the major research hubs, although with different collaboration profiles. Conclusion: This study provides a dual-database bibliometric analysis of cancer microphysiological systems and tumor-on-chip research from 2010 to 2025. The field has expanded from microfluidic engineering and basic tumor reconstruction toward tumor microenvironment modeling, multicellular interactions, drug-related applications, and organoid integration. These trends indicate growing translational interest, although the biological performance and clinical utility of individual platforms require direct experimental evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.